Literature DB >> 2819841

Successful treatment of scleroderma renal crisis with enalapril.

S R Milsom, M G Nicholls.   

Abstract

A patient with scleroderma renal crisis is described. At presentation he had severe hypertension, deteriorating renal function, microangiopathic haemolytic anaemia, and elevated levels of renin, aldosterone and noradrenaline. Enalapril controlled blood pressure, stabilized renal function, lowered aldosterone and noradrenaline levels, and improved peripheral circulation. It appears that converting-enzyme inhibitors can favourably alter the outlook of this otherwise fatal disorder.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2819841      PMCID: PMC2418962          DOI: 10.1136/pgmj.62.733.1059

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.

Authors:  J A Lopez-Ovejero; S D Saal; W A D'Angelo; J S Cheigh; K H Stenzel; J H Laragh
Journal:  N Engl J Med       Date:  1979-06-21       Impact factor: 91.245

2.  Captopril in the treatment of scleroderma renal crisis.

Authors:  R H Thurm; J C Alexander
Journal:  Arch Intern Med       Date:  1984-04

3.  Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK, 421 (Enalapril) in captopril-intolerant patients.

Authors:  C D Smith; R D Smith; J H Korn
Journal:  Arthritis Rheum       Date:  1984-07

4.  Medical treatment of hypertension and renal failure in scleroderma.

Authors:  A J Barnett
Journal:  Aust N Z J Med       Date:  1981-08

5.  Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases.

Authors:  Y M Traub; A P Shapiro; G P Rodnan; T A Medsger; R H McDonald; V D Steen; T A Osial; S F Tolchin
Journal:  Medicine (Baltimore)       Date:  1983-11       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.